T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NLSN
876
DELISTED
Nielsen Holdings plc
NLSN
| $48.3M | 0.01% |
996,988
+369,688
| +59% | +$17.2M |
|
877
BJ's Restaurants
BJRI
$1.48B
| $48M | 0.01% |
1,374,013
-18,370
| -1% | -$585K |
|
878
FTI Consulting
FCN
$4.22B
| $47.6M | 0.01% |
1,258,386
+93,061
| +8% | +$3.07M |
|
879
National Healthcare
NHC
$3.47B
| $47.4M | 0.01% |
841,867
+3,400
| +0.4% | +$185K |
|
880
Fossil Group
FOSL
$311M
| $47.4M | 0.01% |
453,238
-607,597
| -57% | -$64.9M |
|
881
Washington Trust Bancorp
WASH
$750M
| $47.2M | 0.01% |
1,283,780
+3,190
| +0.2% | +$113K |
|
882
Novavax
NVAX
$1.31B
| $47.2M | 0.01% |
510,735
+351,045
| +220% | +$30.9M |
|
883
Hercules Capital
HTGC
$3.11B
| $47.1M | 0.01% |
2,916,500
+62,740
| +2% | +$918K |
|
884
Haverty Furniture Companies
HVT
$441M
| $46.9M | 0.01% |
1,865,020
-5,700
| -0.3% | -$145K |
|
|
KND
885
DELISTED
Kindred Healthcare
KND
| $46.8M | 0.01% |
2,027,680
-794,400
| -28% | -$19.4M |
|
886
Agios Pharmaceuticals
AGIO
$2.04B
| $46.7M | 0.01% |
+1,019,913
| New | +$41.6M |
|
887
Kite Realty
KRG
$5.27B
| $46.7M | 0.01% |
1,900,935
+40,592
| +2% | +$992K |
|
888
RLJ Lodging Trust
RLJ
$1.66B
| $46.7M | 0.01% |
1,615,544
+860,979
| +114% | +$23.4M |
|
889
Aaon
AAON
$7.03B
| $46.3M | 0.01% |
3,107,093
+61,718
| +2% | +$826K |
|
|
LDL
890
DELISTED
Lydall, Inc.
LDL
| $46.2M | 0.01% |
1,686,270
+500
| +0% | +$12.8K |
|
|
DWA
891
DELISTED
DREAMWORKS ANIMATION SKG INC CL-A
DWA
| $46.1M | 0.01% |
1,981,100
-288,500
| -13% | -$7.53M |
|
892
PBF Energy
PBF
$8.81B
| $46M | 0.01% |
1,725,023
-1,052,341
| -38% | -$31.1M |
|
|
SNV
893
DELISTED
Synovus
SNV
| $45.8M | 0.01% |
1,879,365
-15,715
| -0.8% | -$366K |
|
|
NBL
894
DELISTED
Noble Energy, Inc.
NBL
| $45.5M | 0.01% |
587,645
+19,955
| +4% | +$1.45M |
|
895
Ethan Allen Interiors
ETD
$575M
| $45.2M | 0.01% |
1,826,886
+18,200
| +1% | +$445K |
|
896
Fomento Económico Mexicano
FMX
$40B
| $45.2M | 0.01% |
482,600
-76,900
| -14% | -$7.3M |
|
897
Boston Beer
SAM
$1.89B
| $45.2M | 0.01% |
202,137
+1,200
| +0.6% | +$273K |
|
|
KNL
898
DELISTED
Knoll, Inc.
KNL
| $45M | 0.01% |
2,597,390
+103,210
| +4% | +$1.82M |
|
899
TriNet
TNET
$3.07B
| $44.9M | 0.01% |
+1,865,419
| New | +$43.6M |
|
900
Koppers
KOP
$857M
| $44.4M | 0.01% |
1,161,778
-64,380
| -5% | -$2.52M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.